• Nintedanib (BIBF 1120): Optimizing Protocols for Precision A

  2026-05-24

  Explore the scientific basis and advanced assay strategies for Nintedanib (BIBF 1120), a leading triple angiokinase inhibitor. This article uniquely emphasizes protocol optimization and translational insights for cancer and fibrosis research, distinguishing itself from existing resources.

• hiPSC-Derived Intestinal Organoids for Pharmacokinetic Model

  2026-05-23

  This study establishes a streamlined protocol to generate human induced pluripotent stem cell (hiPSC)-derived intestinal organoids for pharmacokinetic studies. The approach enables long-term propagation and maturation into enterocyte-rich epithelial monolayers, providing a physiologically relevant model for drug metabolism and absorption research.

• Biodentine Rejuvenates Aged Dental Pulp Stem Cells via Wnt/β

  2026-05-22

  The referenced study demonstrates that Biodentine can reverse cellular aging and promote proliferation in human dental pulp stem cells (hDPSCs) by activating the Wnt/β-catenin pathway. These findings clarify Biodentine's mechanistic advantage for vital pulp therapy, informing both dental material science and regenerative cell culture protocols.

• Nintedanib (BIBF 1120): Precision Targeting in Fibrosis and

  2026-05-22

  Explore the advanced mechanisms and experimental impact of Nintedanib (BIBF 1120) as a triple angiokinase inhibitor for cancer and idiopathic pulmonary fibrosis research. Discover unique assay strategies and biomarker-driven applications that set this in-depth analysis apart.

• Captopril Beyond Hypertension: ACE Inhibition and GI Motilit

  2026-05-21

  Explore the multifaceted role of Captopril as an ACE inhibitor, delving into its applications in hypertension, oncology, and the modulation of gastrointestinal motility. This article uniquely connects bradykinin B2 receptor signaling with practical research protocols using Captopril.

• Merimepodib (VX-497): Host Metabolic Rewiring and Antiviral

  2026-05-21

  Explore how Merimepodib (VX-497) targets host nucleotide metabolism, offering unique insights into IMPDH inhibition for antiviral, immunosuppressive, and cancer research. This article delves into metabolic reprogramming, recent breakthroughs, and advanced applications.

• Cisapride (R 51619): Strategic Leverage in Cardiac Safety Re

  2026-05-20

  This thought-leadership article explores how Cisapride (R 51619), a nonselective 5-HT4 receptor agonist and potent hERG channel inhibitor, is driving transformative advances in translational cardiac electrophysiology. By connecting mechanistic insights, high-content deep learning assays, and practical protocol guidance, we empower researchers to de-risk drug discovery pipelines and advance cardiac safety pharmacology.

• Annexin V-FITC/PI Apoptosis Assay Kit: Precision Apoptosis D

  2026-05-20

  The Annexin V-FITC/PI Apoptosis Assay Kit enables rapid, flow cytometry-based discrimination of early and late apoptotic cells via dual fluorescence labeling. By detecting phosphatidylserine externalization and membrane integrity loss, this kit provides high sensitivity and reproducibility for apoptosis research. APExBIO's K2003 kit streamlines workflow and supports robust data generation in cancer and cell death studies.

• Reliable Antiangiogenic Assays with Nintedanib (BIBF 1120) S

  2026-05-19

  This article guides biomedical researchers in leveraging Nintedanib (BIBF 1120), SKU A8252, for reproducible cell viability and angiogenesis inhibition studies. Scenario-driven Q&As address common workflow challenges, protocol optimization, and product selection, supported by recent literature and APExBIO’s validated offering.

• Pharmacokinetic Variability of CSBTA in MASH Mouse Models

  2026-05-19

  This study characterizes how metabolic dysfunction-associated steatohepatitis (MASH) alters the pharmacokinetics and tissue distribution of key alkaloids from Corydalis saxicola Bunting (CSBTA) in mice. The research demonstrates that disease state and dosing regimen significantly impact systemic and hepatic drug exposure, providing rationale for optimized clinical dosing strategies in MASLD/MASH contexts.

• Inducing Bleb Structures in LNPs Enhances mRNA Transfection

  2026-05-18

  This study demonstrates that inducing mRNA-rich bleb structures in lipid nanoparticle (LNP) formulations, using high concentrations of pH 4 sodium citrate buffer, significantly improves transfection potency both in vitro and in vivo. The findings emphasize formulation optimization as a critical factor for enhancing mRNA stability and delivery, offering new insights for the development of robust gene expression assays and bioluminescent reporter systems.

• Practical Guide to YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2

  2026-05-18

  YC-1 (5-(1-benzyl-1H-indazol-3-yl)furan-2-yl)methanol is a research-grade soluble guanylyl cyclase activator and hypoxia-inducible factor 1α (HIF-1α) inhibitor for studies on hypoxia signaling, tumor angiogenesis inhibition, and cancer biology. This product is not suitable for diagnostic or therapeutic use and should be applied within its dossier-defined research scope.

• Prochlorperazine: Dopamine D2 Antagonist in Melanoma Researc

  2026-05-17

  Prochlorperazine’s profile as a dopamine D2 receptor antagonist unlocks advanced applications in antiemetic therapy and melanoma research. Explore how workflows that leverage its unique pharmacology—ranging from cell migration assays to antiviral screens—can be optimized for reproducibility, sensitivity, and translational relevance.

• PNU 74654: Wnt Signaling Pathway Inhibitor for Cell Modulati

  2026-05-16

  PNU 74654 is a high-purity small molecule Wnt signaling pathway inhibitor developed by APExBIO. It selectively impedes the Wnt/β-catenin signaling cascade, critical for cell proliferation and differentiation studies. This dossier defines its mechanism, evidence base, and research boundaries.

• Host Actin–Myosin II Network Regulates Duck Enteritis Virus

  2026-05-15

  This study uses proteomic screening to reveal that the duck enteritis virus (DEV) protein VP26 interacts with host cytoskeletal proteins, particularly the actin–myosin II network, to facilitate viral proliferation. The findings highlight how disruption of actin polymerization significantly reduces viral titers, offering mechanistic insight into host–pathogen interactions and experimental strategies for cytoskeleton-targeted research.

16073 records 1/1072 page Next 12345 下5页 Last page